FindMyRecallSubscribe
Class I: serious health riskTerminated

Heritage Pharmaceuticals Amikacin Sulfate Injection Recall

AMIKACIN SULFATE INJECTION, USP, 1 gram/4 mL (250 mg/ml), 4 mL vial, Rx only, Mfd

Heritage Pharmaceuticals, Inc. · East Brunswick, NJ

Risk level
Class I
Reported by FDA
Jun 19, 2019
Recall ID
D-1398-2019
Check your lot numberHow we source this data

Summary

Heritage Pharmaceuticals recalled Amikacin Sulfate Injection starting May 21, 2019. The FDA classified it as Class I (serious health risk) and published enforcement report D-1398-2019 on Jun 19, 2019. Reason: Non-Sterility:Microbial growth detected in sub lot of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) . Status: Terminated.

Why it was recalled

Non-Sterility:Microbial growth detected in sub lot of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) .

Product description

AMIKACIN SULFATE INJECTION, USP, 1 gram/4 mL (250 mg/ml), 4 mL vial, Rx only, Mfd. by: Emcure Pharmaceuticals, Ltd., Hinjawadi, Pune, India Mfd. for: Heritage Pharmaceuticals Inc.. NDC 23155-290-32

Lot numbers, UPCs & expiration codes

Lot: VEAC025, EXP 10-2019

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1398-2019
Classification
Class I
Status
Terminated
Recall initiated
May 21, 2019
FDA report date
Jun 19, 2019
Quantity
14,960 4 mL vials
Recall type
Voluntary: Firm initiated
Recalling firm
Heritage Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-1398-2019, exactly as published.

Show all FDA fields
City
East Brunswick
State
NJ
Status
Terminated
Country
United States
Event ID
82918
Address
1 Tower Center Blvd Ste 1700
Code information
Lot: VEAC025, EXP 10-2019
Postal code
08816-1145
Report date
Jun 19, 2019
Product type
Drugs
Recall number
D-1398-2019
Classification
Class I
Recalling firm
Heritage Pharmaceuticals, Inc.
Product quantity
14,960 4 mL vials
Termination date
Jan 11, 2022
Reason for recall
Non-Sterility:Microbial growth detected in sub lot of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) .
Voluntary / mandated
Voluntary: Firm initiated
Product description
AMIKACIN SULFATE INJECTION, USP, 1 gram/4 mL (250 mg/ml), 4 mL vial, Rx only, Mfd. by: Emcure Pharmaceuticals, Ltd., Hinjawadi, Pune, India Mfd. for: Heritage Pharmaceuticals Inc.. NDC 23155-290-32
Distribution pattern
Nationwide in the USA
Recall initiation date
May 21, 2019
Initial firm notification
Press Release
Center classification date
Jun 19, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1398-2019, published Jun 19, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls